Doximity, Inc. 10-Q Summary: Q1 2025 (Ended June 30, 2024)
Business Context and Reporting Period
This filing covers the first quarter of Doximity's fiscal year 2025, ended June 30, 2024. Doximity operates the leading digital platform for U.S. medical professionals, serving over 80% of U.S. physicians. The company generates revenue primarily through Marketing Solutions (content delivery to physicians) and Hiring Solutions (recruiting tools) sold to pharmaceutical companies and health systems.
Key Financial Metrics
| Metric | Q1 2025 (Jun 30, 2024) | Q1 2024 (Jun 30, 2023) |
|---|---|---|
| Revenue | $126.7 million | $108.5 million |
| Gross Profit | $113.1 million | $95.3 million |
| Gross Margin | 89% | 88% |
| Net Income | $41.4 million | $28.4 million |
| Diluted EPS | $0.21 | $0.13 |
| Adjusted EBITDA | $65.9 million | $46.6 million |
| Adjusted EBITDA Margin | 52% | 43% |
| Free Cash Flow | $39.5 million | $55.6 million |
| Cash & Marketable Securities | $750.5 million | $306.7 million (Cash only) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17% year-over-year, driven by a $18.7 million increase in subscription revenue. This was split between $5.5 million from new customers and $13.2 million from expansion of existing customers (average revenue per Marketing Solutions customer rose ~19%).
- Profitability: Net income increased 46% to $41.4 million. Net income margin expanded from 26% to 33%.
- Operating Expenses: Total operating expenses increased slightly to $67.1 million. Sales and marketing expenses rose 2% due to higher incentive compensation and stock-based compensation, partially offset by a reduction in personnel costs from a prior restructuring.
- Other Income: Other income, net, increased 47% to $7.1 million, primarily due to higher interest income on the company's cash and marketable securities portfolio.
- Share Repurchases: The company completed a previous $410 million repurchase program in April 2024 and initiated a new $500 million program in May 2024. During Q1, the company repurchased approximately 1.85 million shares for $51.2 million.
Outlook, Risks, and Contingencies
- Legal Proceedings: In April and May 2024, the company and certain directors/officers were named in two lawsuits in the Northern District of California. One is a putative securities class action alleging misrepresentations regarding growth and profitability; the other is a derivative suit alleging breach of fiduciary duties. The company intends to defend vigorously but cannot estimate potential losses at this early stage.
- Liquidity: Management believes existing cash and marketable securities ($750.5 million) are sufficient to meet working capital and capital expenditure needs for at least the next 12 months.
- Tax Considerations: The company noted increased cash tax payments due to the Tax Cuts and Jobs Act of 2017, which requires capitalization and amortization of R&D expenditures. Future cash flows may be impacted if Congress does not defer this requirement.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks related to competition, regulatory changes, data security, and the ability to retain members and customers.
Investor Verification Checklist
- Legal Exposure: Monitor the status and potential settlement costs of the securities class action and derivative lawsuits filed in Q1 2025.
- Customer Concentration: Verify the stability of the top customers, as two customers represented 14% of accounts receivable each as of June 30, 2024.
- Share Buyback Execution: Track the pace of the new $500 million share repurchase program authorized in May 2024.
- Interest Rate Sensitivity: Assess the impact of potential interest rate changes on the company's investment income, which contributed significantly to "Other income, net."
- R&D Tax Treatment: Evaluate the long-term cash flow impact of the R&D capitalization rules under the Tax Cuts and Jobs Act.